Berkshire Hathaway Inc Class B vs Mesoblast Limited — how do they compare? Berkshire Hathaway Inc Class B trades at $509.58, while Mesoblast Limited trades at $16.88 (market cap $2.21B). The key difference: Berkshire Hathaway Inc Class B is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| BRK.B | MESO | |
|---|---|---|
Sector | Financials | Technology |
52-Week High | $529.65 | $20.96 |
52-Week Low | $465.39 | $12.88 |
Market Cap | — | $2.21B |
Enterprise Value | — | $2.21B |
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $529.65, up 1.73% today, with a bullish technical signal from moving averages and oscillators. The stock is near its pivot point of $530, with support at $522 and resistance at $536. Analyst consensus is positive, with 57% of 7 analysts rating it a Buy and none recommending Sell, indicating strong institutional confidence.
The outlook remains favorable given the bullish technicals and analyst support, though overbought RSI readings suggest near-term caution. Key risks include market volatility and macroeconomic pressures, but the stock's strong fundamentals and institutional backing provide a solid foundation for potential growth.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Trailing returns across standard periods
Latest headlines on both assets
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →